ConductScience.org, home

Paper32201284

Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.

Cucchetti A and 16 others. J Hepatol, 2020. Cited by 67 papers, by iCite.

Cite this record

ConductScience Library. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Papers, record 32201284. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32201284

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
PubMed
Journal
J Hepatol
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
67
iCite
Relative citation ratio, by iCite
3.39
iCite
Revised in PubMed
2021-11-03
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cucchetti AAlessandro
2Serenari MMatteo
3Sposito CCarlo
4Di Sandro SStefano
5Mosconi CCristina
6Vicentin IIlaria
7Garanzini EEnrico
8Mazzaferro VVincenzo
9De Carlis LLuciano
10Golfieri RRita
11Spreafico CCarlo
12Vanzulli AAngelo
13Buscemi VVincenzo
14Ravaioli MMatteo
15Ercolani GGiorgio
16Pinna ADAntonio Daniele
17Cescon MMatteo

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Liver TransplantationMajor topic
Neoadjuvant TherapyMajor topic
Neoplasm Recurrence, LocalMajor topic
Technology, RadiologicMajor topic
Cause of Death
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Postoperative Complications
Predictive Value of Tests
Prognosis
Risk Assessment
Tumor Burden
Ultrasonography
alpha-Fetoproteins

Source PubMed

Download CSV of topics

Cited by40

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 67 citations.

PMIDTitleJournalYearIn PapersSource
42008358SREBP2 as a Novel Biomarker for Posttransplant Hepatocellular Carcinoma Recurrence: A New Prognostic Nomogram.Biomed Res Int2026https://conductscience.org/library/papers/42008358PubMed
41999190A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma.Technol Cancer Res Treat2026https://conductscience.org/library/papers/41999190PubMed
41301037Transforming Liver Cancer Therapy: Integrating Molecular Profiling with Precision and Transplant-Based Care.Cancers (Basel)2025https://conductscience.org/library/papers/41301037PubMed
40721563Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.Discov Oncol2025https://conductscience.org/library/papers/40721563PubMed
40427217The Italian Score for Organ Allocation: A Ten-Year Monocentric Retrospective Analysis in Liver Transplantation for Hepatocellular Carcinoma.Cancers (Basel)2025https://conductscience.org/library/papers/40427217PubMed
40380811Liver transplantation as a treatment for cancer: comprehensive review.BJS Open2025https://conductscience.org/library/papers/40380811PubMed
39494583New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver Int2025https://conductscience.org/library/papers/39494583PubMed
38983320Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer.World J Gastrointest Surg2024https://conductscience.org/library/papers/38983320PubMed
38829544Combined transarterial chemoembolization and thermal ablation in candidates to liver transplantation with hepatocellular carcinoma: pathological findings and post-transplant outcome.Radiol Med2024https://conductscience.org/library/papers/38829544PubMed
38606106A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Front Oncol2024https://conductscience.org/library/papers/38606106PubMed
38473400Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes.Cancers (Basel)2024https://conductscience.org/library/papers/38473400PubMed
38435683A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization.J Hepatocell Carcinoma2024https://conductscience.org/library/papers/38435683PubMed
38137868Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation.Life (Basel)2023https://conductscience.org/library/papers/38137868PubMed
37370775Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant.Cancers (Basel)2023https://conductscience.org/library/papers/37370775PubMed
37039979Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database.J Gastrointest Surg2023https://conductscience.org/library/papers/37039979PubMed
37034235Main factors influencing long-term outcomes of liver transplantation in 2022.World J Hepatol2023https://conductscience.org/library/papers/37034235PubMed
36967432The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.World J Surg Oncol2023https://conductscience.org/library/papers/36967432PubMed
36849836Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma.Cardiovasc Intervent Radiol2023https://conductscience.org/library/papers/36849836PubMed
36691474AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.JHEP Rep2023https://conductscience.org/library/papers/36691474PubMed
36514693Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress.J Hepatocell Carcinoma2022https://conductscience.org/library/papers/36514693PubMed

See all 40 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32201284

GET https://conductscience.org/api/papers/v1/32201284/cited_by?page=2